Close Menu

NEW YORK – Liquid biopsy startup OncoCell MDx announced today that it has raised $22.2 million in a Series B financing round.

Royal Oak, Michigan-based OncoCell MDx will use the funding to support development and commercialization of its pan-disease diagnostic testing platform. The firm anticipates launching a blood test for detecting and grading aggressive prostate cancer next year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.